Trial Profile
A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Artefenomel (Primary) ; Ferroquine (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Acronyms FALCI
- Sponsors Sanofi
- 06 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2019 Planned End Date changed from 2 Apr 2021 to 1 May 2020.